James Clark, who has experience commercialising diagnostic and therapeutic products, has joined PredictImmune Ltd as chief technology officer where he will help oversee development of a test for inflammatory bowel disease. Mr Clark joins PredictImmune from EnteroBiotix Ltd, developers of microbiome modulating therapies, where he was chief executive. Prior to this, he was chief technology officer at Enterome SA.
PredictImmune announced the appointment on 14 November 2019.